Early Relapse Signals High-Risk Primary Refractory LBCL

A secondary analysis of a phase 3 trial suggests that patients with relapse within 3 months of treatment or persistent disease represent a distinct high-risk group.
Medscape Medical News

source https://www.medscape.com/viewarticle/early-relapse-signals-high-risk-primary-refractory-lbcl-2026a1000as0?src=rss

Comments

Popular posts from this blog

New AAFP practice guideline sets blood pressure targets for adults with hypertension